# Q&A Anticipation Layer

This section anticipates hard investor questions and points to evidence to avoid improvisation.

## Likely Questions & Evidence

1. **What does “GA” mean in this context?**
   - Evidence: [GA criteria](../../GA_CRITERIA.md), [GA release checklist](../../GA_RELEASE_CHECKLIST.md)
2. **What are the top three risks and how are they managed?**
   - Evidence: [Risk register (investor view)](risk-register-investor-view.md), [Risk ledger](../../RISK_LEDGER.md)
3. **How do you prevent overclaiming in demos and marketing?**
   - Evidence: [GTM claims matrix](../../GTM_CLAIMS_MATRIX.md), [Operating principles](operating-principles-controls.md)
4. **What evidence supports governance and compliance readiness?**
   - Evidence: [Compliance controls](../../COMPLIANCE_CONTROLS.md), [Compliance evidence index](../../COMPLIANCE_EVIDENCE_INDEX.md)
5. **How do you scale without compromising reliability?**
   - Evidence: [Observability strategy](../../OBSERVABILITY.md), [Performance budget](../../PERFORMANCE_BUDGET.md)
6. **What is intentionally not shared and why?**
   - Evidence: [Redaction rules](redaction-boundary-rules.md)

## Follow-Up Evidence Locations

- **Product scope**: [MVP3 GA execution artifacts](../../MVP3_GA_EXECUTION_ARTIFACTS.md)
- **Security posture**: [SECURITY.md](../../SECURITY.md)
- **Governance**: [GOVERNANCE.md](../../GOVERNANCE.md)
